Clinical Stage Neuspera Medical is a privately held, venture-backed clinical-stage neuromodulation company with an FDA IDE enabling its first long-term clinical trial of an ultra-miniaturized implantable platform. This signals readiness for academic medical centers and early-adopter hospitals to participate in trials and pilot programs; a strong path for building trial sites and CRO partnerships to advance UUI and broader platform applications.

UUI Focus Urinary Urgency Incontinence is the first indication, placing primary sales targets in urology and pelvic health clinics within hospitals and multi-specialty centers. The combination of a minimally invasive implant and external wearable transmitter offers a compelling value proposition for patients and payers seeking less invasive therapies; target trial sites, engage key opinion leaders, and coordinate reimbursement discussions early.

Growth Funding The company has secured significant venture financing, including a 65 million Series C in 2021, and ongoing private backing, signaling growth momentum and potential for strategic partnerships. This provides a foundation for co-development, distribution deals, or licensing discussions with established medtech players to accelerate commercialization post-regulatory milestones.

Global Footprint Headquartered in Puebla, Mexico with a lean 11-50 person team, suggesting opportunities for regional manufacturing, near-shoring supply, or Latin American distribution partnerships. BD efforts can explore regional regulatory and CRO networks, local manufacturing partners, and hospital networks seeking access to neuromodulation therapies through trials and eventual commercialization.

Differentiated Platform The ultra-miniaturized implantable platform designed for deep anatomical targets, coupled with external wearables, positions Neuspera to differentiate from larger incumbents. This creates opportunities for licensing, co-marketing, or exclusive distribution with partners focused on niche indications or expansion into additional chronic conditions, emphasizing reduced invasiveness and remote connectivity.